IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05987332 |
Recruitment Status :
Recruiting
First Posted : August 14, 2023
Last Update Posted : March 27, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Uveal Melanoma | Drug: IDE196 Drug: Crizotinib Drug: Pembrolizumab Drug: Ipilimumab Drug: Nivolumab Drug: Dacarbazine | Phase 2 Phase 3 |
This study is designed as a multi-stage Phase 2 study within a Phase 3 study to evaluate the safety, tolerability, pharmacokinetics, dose-exposure relationship, and anti-tumor activity of IDE196 in combination with crizotinib compared to the comparator arm of investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
The Phase 2a dose optimization stage will evaluate two doses of IDE196 in combination with crizotinib compared to the comparator arm. Participants will be randomized to the three treatment arms. At the point of optimal IDE196 + crizotinib dose selection, the other dose arm will be dropped with discontinuation of enrollment to that arm. Participants receiving the IDE196 dose (in combination with crizotinib) that is not selected, will be offered the choice to remain on the same dose or change to the chosen optimal dose.
The optimal dose will be chosen to complete the Phase 2b portion. The Phase 2b part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms.
The Phase 3 part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 380 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2) |
Actual Study Start Date : | October 31, 2023 |
Estimated Primary Completion Date : | January 15, 2027 |
Estimated Study Completion Date : | January 15, 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: Phase 2a Dose Optimization of IDE196 + crizotinib
Multiple doses of IDE196 will be tested in combination with fixed dose of crizotinib to identify the optimal combination dose.
|
Drug: IDE196
Dosed orally, twice daily
Other Name: Darovasertib Drug: Crizotinib Dosed orally, twice daily
Other Name: XALKORI |
Experimental: Phase 2b / 3 Chosen Combination dose of IDE196 + crizotinib
Chosen combination dose of IDE196 + crizotinib will be tested in additional participants.
|
Drug: IDE196
Dosed orally, twice daily
Other Name: Darovasertib Drug: Crizotinib Dosed orally, twice daily
Other Name: XALKORI |
Active Comparator: Phase 2a / 2b / 3 Comparator Arm
Participants will receive investigator's choice of Pembrolizumab, Ipilimumab + Nivolumab, or Dacarbazine.
|
Drug: Pembrolizumab
IV administration every 3 weeks
Other Name: Keytruda Drug: Ipilimumab IV administration every 3 weeks for 4 Cycles
Other Name: Yervoy Drug: Nivolumab IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance
Other Name: Opdivo Drug: Dacarbazine IV administration every 3 Weeks
Other Name: DTIC-Dome |
- Progression-Free Survival (PFS) by blinded independent central review (BICR) of IDE196 + Crizotinib compared to investigator's choice of treatment [ Time Frame: Approximately 2 years ]PFS per RECIST 1.1
- Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment [ Time Frame: Approximately 4 years ]OS from randomization to date of death due to any cause
- Safety of IDE196 + Crizotinib: Incidence of Adverse Events [ Time Frame: Approximately 2 years ]Treatment emergent adverse events will be summarized by all AEs, all Grade 3-4-5 AEs, all treatment related AEs, all AEs leading to study drug modifications or discontinuations, all SAEs as measured by CTCAE V5.0
- Phase 2a: Dose exposure response of IDE196 [ Time Frame: Approximately 5 months ]Dose-exposure-response of IDE196 as measured by concentration of IDE196 in plasma
- Phase 2a: Dose exposure response of Crizotinib [ Time Frame: Approximately 5 months ]Dose-exposure-response of Crizotinib as measured by concentration of Crizotinib in plasma
- Progression-Free Survival (PFS) per Investigator of IDE196 + Crizotinib compared to investigator's choice of treatment [ Time Frame: Approximately 2 years ]PFS per RECIST 1.1
- Objective Response Rate (ORR) per BICR and Investigator assessment of IDE196 + Crizotinib compared to investigator's choice of treatment [ Time Frame: Approximately 2 years ]ORR per RECIST 1.1
- Duration of Response (DOR) per BICR and Investigator assessment of IDE196 + Crizotinib compared to investigator's choice of treatment [ Time Frame: Approximately 2 years ]DOR per RECIST 1.1
- Change from baseline over time and between treatment arms in EORTC QLQ-C30 [ Time Frame: Approximately 2 years ]Global health status and quality of life will be assessed using the EORTC QLQ-C30 questionnaire. The score range for the EORTC QLQ-C30 is from 0 to 100, with higher scores indicating better functioning and better global health status and health-related quality of life. A positive change indicates improvement.
- Change from baseline over time and between treatment arms in EuroQoL (EQ)-5D-5L scores [ Time Frame: Approximately 2 years ]General health status will be assessed using the EQ-5D,5L questionnaire, which includes five dimensions (5D): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 scoring levels, where 1 indicates a better health state (no problems) and 3 indicates a worse health state. A positive change indicates improvement.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histological or cytological confirmed Metastatic Uveal Melanoma
- HLA-A*02:01 negative
- No prior systemic therapy in the metastatic or advanced setting, regional or liver-directed therapy, ablations or surgical resection of oligometastatic disease, or neoadjuvant or adjuvant therapy is allowed
- Measurable disease per RECIST 1.1
- Able to be safely administered and absorb study therapy
- ECOG performance status 0 or 1
- Life expectancy of ≥3 months
- Adequate organ function
Exclusion Criteria:
- Previous treatment with a PKC inhibitor (including prior treatment with IDE196), an inhibitor directly targeting MET, or an inhibitor directly targeting GNAQ/11
- Concurrent malignant disease
- AEs from prior anti-cancer therapy that have not resolved to Grade ≤1
- Symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require corticosteroids
- Active HIV infection or Hep B/C
- Active adrenal insufficiency, active colitis, or active inflammatory bowel disease
- History of interstitial lung disease, active pneumonitis, or history of pneumonitis
- Active infection requiring systemic antibiotic therapy
- Use of hematopoietic colony-stimulating factors (CSF) prior to start of study drug
- Females who are pregnant or breastfeeding
- History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies
- Contraindication for treatment with investigator's choice therapies as per applicable labelling
- Has any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the opinion of the investigator, would make the participant inappropriate for entry into the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05987332
Contact: IDEAYA Clinical Trials | 1 650-534-3616 | IDEAYAClinicalTrials@ideayabio.com | |
Contact: Darrin Beaupre, MD, Ph.D | 650-443-6306 | dbeaupre@ideayabio.com |
Study Director: | Darrin Beaupre, MD, Ph.D | IDEAYA Biosciences |
Responsible Party: | IDEAYA Biosciences |
ClinicalTrials.gov Identifier: | NCT05987332 |
Other Study ID Numbers: |
IDE196-002 |
First Posted: | August 14, 2023 Key Record Dates |
Last Update Posted: | March 27, 2024 |
Last Verified: | February 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
IDE196 Darovasertib Protein Kinase C Metastatic Uveal Melanoma Melanoma |
Ocular Oncology Ophthalmology Crizotinib Ocular melanoma |
Melanoma Uveal Neoplasms Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas Skin Neoplasms Neoplasms by Site Skin Diseases Eye Neoplasms Eye Diseases Uveal Diseases |
Pembrolizumab Nivolumab Ipilimumab Dacarbazine Crizotinib Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Alkylating Alkylating Agents Tyrosine Kinase Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors |